Evidence map›Paper›PMID 38628557›Full record

ArticleJournal of kidney cancer and VHL2024

Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer: A Case Report.

Sara Demurtas, Mara Frascaroli, Federico Sottotetti, Alessandro Rametta, Giuseppe Procopio, Laura Deborah Locati

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of kidney cancer and VHL, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sara DemurtasInternal Medicine and Therapeutics Department, University of Pavia, Pavia, Italy.
Mara FrascaroliMedical Oncology, Maugeri Clinical Research Institutes IRCCS, Pavia; Italy.
Federico SottotettiMedical Oncology, Maugeri Clinical Research Institutes IRCCS, Pavia; Italy.
Alessandro RamettaMedical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Giuseppe ProcopioMedical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Laura Deborah LocatiInternal Medicine and Therapeutics Department, University of Pavia, Pavia, Italy.
Clinical Research Institute · USFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal carcinoma (ccRCC) can occur in young people and could be associated with an aggressive behavior. While for the first-line treatment in metastatic disease, there is an agreement to rely on an immunotherapy (IO)-based combination regimen, no standard second-line regimens exist. Generally, tyrosine kinase inhibitors (TKIs) are employed, even in sequence, although no trials have demonstrated yet the best succession. Herein, we present the case of a 39-year-old male, with a very aggressive ccRCC with somatic

Indexed as

case reportlenvatinibrenal cell carcinomatyrosine kinase inhibitorVHL mutation

Identifiers

PMID38628557
PMCPMC11017133
OpenAlexW4394715508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.